Home  |  Contact

Cellosaurus UKF-NB-3 (CVCL_9904)

[Text version]

Cell line name UKF-NB-3
Synonyms UKF-NB3
Accession CVCL_9904
Resource Identification Initiative To cite this cell line use: UKF-NB-3 (RRID:CVCL_9904)
Comments Doubling time: 22 +- 1.9 hours (PubMed=16142320).
Disease Neuroblastoma (NCIt: C3270)
Derived from metastatic site: Bone marrow.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_RQ64 (UKF-NB-3rMEL400)CVCL_RS05 (UKF-NB-3rNutlin10muM)CVCL_RQ65 (UKF-NB-3rOXALI2000)
Category Cancer cell line

Cinatl J., Gussetis E.S., Cinatl J. Jr., Ebener U., Mainke M., Schwabe D., Doerr H.-W., Kornhuber B., Gerein V.
Differentiation arrest in neuroblastoma cell culture.
J. Cancer Res. Clin. Oncol. 116 Suppl. 1:9-9(1990)

Cinatl J. Jr., Cinatl J., Scholz M., Driever P.H., Henrich D., Kabickova H., Vogel J.-U., Doerr H.-W., Kornhuber B.
Antitumor activity of sodium valproate in cultures of human neuroblastoma cells.
Anticancer Drugs 7:766-773(1996)

Cinatl J. Jr., Hernaiz Driever P., Cinatl J., Ruckert D.G., Gumbel H.O., Rabenau H., Kornhuber B., Doerr H.-W.
Increased efficacy of aphidicolin killing of human neuroblastoma cells in vitro by encapsulation in liposomes.
Neoplasma 44:91-95(1997)

PubMed=16142320; DOI=10.3892/ijo.27.4.1029
Kotchetkov R., Driever P.H., Cinatl J., Michaelis M., Karaskova J., Blaheta R.A., Squire J.A., von Deimling A., Moog J., Cinatl J. Jr.
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.
Int. J. Oncol. 27:1029-1037(2005)

Bedrnicek J., Vicha A., Jarosova M., Holzerova M., Cinatl J. Jr., Michaelis M., Cinatl J., Eckschlager T.
Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.
Neoplasma 52:415-419(2005)

PubMed=17505515; DOI=10.1038/sj.bjc.6603777
Blaheta R.A., Michaelis M., Natsheh I., Hasenberg C., Weich E., Relja B., Jonas D., Doerr H.-W., Cinatl J. Jr.
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.
Br. J. Cancer 96:1699-1706(2007)

PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856
Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K., Fehse B., Kammerer B., Doerr H.-W., Cinatl J. Jr.
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Cancer Res. 69:416-421(2009)

PubMed=22170099; DOI=10.1038/cddis.2011.129
Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M., Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F., Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D., Cinatl J. Jr.
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Cell Death Dis. 2:E243-E243(2011)

PubMed=22476102; DOI=10.1038/cddis.2012.35
Michaelis M., Rothweiler F., Agha B., Barth S., Voges Y., Loschmann N., von Deimling A., Breitling R., Doerr H.-W., Rodel F., Speidel D., Cinatl J. Jr.
Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
Cell Death Dis. 3:E294-E294(2012)

PubMed=24466371; DOI=10.1593/tlo.13544
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)

PubMed=25749379; DOI=10.18632/oncotarget.2889
Michaelis M., Rothweiler F., Loschmann N., Sharifi M., Ghafourian T., Cinatl J. Jr.
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.
Oncotarget 6:17605-17620(2015)

PubMed=27517323; DOI=10.18632/oncotarget.11160
Loschmann N., Michaelis M., Rothweiler F., Voges Y., Balonova B., Blight B.A., Cinatl J. Jr.
ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.
Oncotarget 7:58051-58064(2016)

PubMed=27735941; DOI=10.1038/cddis.2016.257
Voges Y., Michaelis M., Rothweiler F., Schaller T., Schneider C., Politt K., Mernberger M., Nist A., Stiewe T., Wass M.N., Rodel F., Cinatl J. Jr.
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.
Cell Death Dis. 7:E2410-E2410(2016)

Other Wikidata; Q54990311
Entry history
Entry creation06-Jun-2012
Last entry updated07-Sep-2018
Version number9